Keyphrases
Glioblastoma
100%
Tumor
59%
Radiation Therapy
43%
Newly Diagnosed Glioblastoma
42%
Temozolomide
41%
Proteogenomics
38%
Glioma
35%
Recurrent Glioblastoma
34%
Glioblastoma multiforme
30%
Neuro-oncology
28%
Glioma Stem Cells
25%
Oncolytic Activity
25%
Zika Virus
25%
Clear Cell Renal Cell Carcinoma (ccRCC)
25%
Phase 1/2 Study
25%
Concurrent Radiation
25%
Disulfiram
25%
Overall Survival
25%
Progression-free Survival
22%
Oncogene
21%
BRAF mutant
19%
Clinical Trials
17%
Epigenetic Drivers
17%
Machine Learning
17%
Essential Pathway
17%
CHD4
17%
Photothermal Therapy
17%
Phase II Study
17%
Epigenetics
17%
Doxorubicin
17%
Transcriptomic Characterization
17%
Progression Markers
17%
Brain Tumor
16%
Tumor Subtype
15%
Isocitrate Dehydrogenase 1 (IDH1)
15%
Maximum Tolerated Dose
14%
Lung Cancer
14%
CD8+ T Cells
14%
Catenin
14%
Precision Medicine
14%
Genetic Modification
13%
Molecular Mechanism
12%
Wnt Signaling
12%
IDH-mutant Glioma
11%
Tumor Cells
11%
Tumor Ecosystem
11%
Salvage Therapy
11%
St. Louis
11%
Cell State
11%
Cancer Transition
11%
Medicine and Dentistry
Glioblastoma
88%
Neoplasm
70%
Ganglioglioma
41%
Malignant Neoplasm
40%
Neuro-Oncology
27%
Zika Virus
25%
Stem Cell
21%
Proteogenomics
19%
Cytotoxic T-Cell
17%
4 Iodo 2,5 Dimethoxyamphetamine
17%
Clear Cell Renal Cell Carcinoma
17%
Medicine
17%
Intracranial Tumor
16%
Temozolomide
16%
Clinical Trial
15%
Radiation Therapy
15%
Transcriptomics
14%
Immunotherapy
13%
Personalized Medicine
12%
Systemic Therapy
12%
Wnt Signaling
11%
Oncogene
11%
Proteomics
11%
Surgery
11%
Oligoastrocytoma
10%
Oligodendroglioma
10%
Brain Metastasis
10%
Overall Survival
8%
Clinician
8%
Salvage Therapy
8%
COVID-19
8%
Combined Therapy
8%
Central Nervous System Cancer
8%
Doxorubicin
8%
Patient-Reported Outcome
8%
Oncology
8%
Functional Status
8%
Brainstem
8%
Hope
8%
Neurological Complication
8%
Interleukin 7
8%
Resting State fMRI
8%
Isocitrate Dehydrogenase
8%
Cell Population
8%
Carcinoma Cell
8%
Cytochrome C Oxidase
8%
Pancreas Cancer
8%
Immune Checkpoint Blockade
8%
Burnout
8%
Biomarker Study
8%